Wednesday 14th June				
8:00 – 9:45	**Registration**			
9:45 – 10:45	**Building a Better Bridge: Innovations in Trial Designs to Address Access and Clinical Practice Questions (Launch & Lifestyle SIG)**	**High Dimensional Data**	**Learning From Mistakes**	
	Jenny Devenport (Roche) Cornelia Dunger-Baldauf (Novartis) Alexander Schacht (Sanevidence)	Chris Harbron (Roche) *Machine Learning and Artificial Intelligence in Clinical Statistics. An opportunity or an over-hyped distraction?* Kaya Miah (German Cancer Research Centre, DKFZ) *Model selection strategies for multi-state endpoints incorporating molecular data* Robin Mitra (University College London) *Addressing Structured Missingness in large complex health databases*	Sue McKendrick (PPD) Mary Oldham (GSK) Emma Jones (Veramed)	
10:45 – 11:00	**Changeover**			
11:00 – 12:30	**The Art of Selecting a Subgroup (Subgroup SIG)**	**What is real - RWD or RCT? How to communicate evidence generation involving RWD (RWD + Launch & Lifestyle SIG)**	**Adaptive Designs: What, Why, When and How Should I use Them?**	**Estimands – The Journey Continues or Doing now what Trial Teams Need Next (Oncology Estimand SIG)**
	Paolo Eusebi (Modus Outcomes) *Data-Driven Subgroup Identification in Clinical Trials: the Good, the Bad, the Ugly*	Josephine Wolfram (Astellas) *Introduction*	Dr Thomas Burnett (University of Bath) Dr Sofia Villar (University of Cambridge)	Lynda Grinsted (AstraZeneca) Stefan Englert (Janssen) Elizabeth Pilling (AstraZeneca)

	Nicole Krämer (Boehringer Ingelheim) *Using simulation studies to evaluate subgroup identification methods*	Min-Hua Jen (Eli Lilly) *Case Study*	Professor Christopher Jennison (University of Bath)	Hong Tian (BeiGene) Yufei Wang (GSK) Konstantina Skaltsa (IQVIA)
	Yuejia Xu (AstraZeneca) *Honest Estimation of Treatment Effects in Subgroups*	Alexander Schacht (Sanevidence) *Good Communication Practice*		
12:30 – 13:30	**Lunch (HTA ESIG Social catch-up)**			
13:30 – 14:30	**PSI/RSS Prize Winner**	**Master Protocols**	**Vaccine SIG**	**Non-technical TED talks**
	Marcel Wolbers (Roche) & Alessandro Noci (Roche) *Standard and reference-based imputation methods based on conditional mean imputation*	Jason Cooper (AstraZeneca) *Feasibility of a Platform Phase II trial for Moderate-to-Severe Asthma: Obstacles and Opportunities*	Hege Michiels (Ghent University) *Estimation and Interpretation of Vaccine Efficacy in COVID-19 Randomized Clinical Trials*	Kimberley Hacquoil (Exploristics) *Deal or No Deal: Make a Decision*
				Emma May (ICON) *Building community in a virtual environment*
		Michaela Maria Freitag (Charité University) Design Considerations for a P*hase II Platform Trial in Major Depressive Disorder*	Andrea Callegaro (GSK) *Bayesian Dynamic Borrowing (BDB) and Vaccine Effectiveness: The Boostrix Maternal Immunization US case*	Ian Ratcliffe (Veramed) *I Want to Fail!*
				Bob Murray (Janssen) *Communication of Statistics: The Formula for Success*

		Peter Jacko (Berry Consultants) *Designing and Simulating a Platform Trial for Rare Diseases*	Daniel Backenroth (Janssen) *Negative Control Methods for Assessing the Robustness of Open-Label Analysis of COVID-19 Vaccine Trial*	Amy Newlands (GSK) *Increasing Statistics Capability in sub-Sahara Africa - The Next Wave* Eileen Holmes (PHASTAR) *Supporting People in FSP Roles*
14:30 – 15:00	**Break**			
15:00 – 16:15	**EU HTA: readying ourselves for the road to 2025 and beyond** Anders Gorst-Rasmussen (Novo Nordisk) *In the crystal ball: how the world might look for a pharmaceutical statistician when EU HTA is here* Ralf Bender (IQWiG) *German requirements for direct and indirect comparisons in HTA dossiers* Zoe Garrett (NICE) Where can collaboration add value to HTA – A look at the UK, Australia and Canada Justine Rochon (Boehringer Ingelheim) *Statistical leadership: Do we hold the key to the future of HTA?*			
16:15 – 16:30	**Closing Remarks**			